RxDoctor Payments Data

Debra Harvey, MD

Family Medicine · Houston, TXNPI 1134142961

Payments from drug & device makers

$1,000in general payments, 2019–2025

Across 43 payments — averaging $23.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$260
  • Davol Inc.$146
  • Supernus Pharmaceuticals, Inc.$131
  • Novo Nordisk$122
  • Pfizer$80
  • Astellas Pharma US Inc$77
  • plus $185 from 5 others

What the payments were for

  • Food & beverage$1,000100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,000 in reported general payments places this provider in the 60th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$11,050
Medicare patients
50
Services billed
182

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide32$58,400
FarxigaDapagliflozin Propanediol31$27,015
Tresiba Flextouch U-100Insulin Degludec12$3,178
Atorvastatin Calcium114$1,447
Losartan Potassium81$1,286
Rosuvastatin Calcium52$686
SynthroidLevothyroxine Sodium18$678
Metoprolol Succinate35$674
Levothyroxine Sodium58$650
Esomeprazole Magnesium13$636
Amlodipine Besylate54$505
Omeprazole37$474
Gabapentin21$469
Duloxetine Hcl12$358
Clonazepam31$340

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$122$58,40032 claims
AstraZenecaFarxiga$72$27,01531 claims
AbbVieSynthroid$260$67818 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Houston

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →